Neurovance’s EB-1020 SR for adult ADHD shows stimulant-like efficacy and good tolerability in Phase 2a Trial

09-05-2014 Business Wire HealthComments (0)

BiotechnologyNeurologicalUSA

Neurovance presented data from its phase 2a study of non-stimulant EB-1020 SR at the Society of Biological Psychiatry meeting. It showed a statistically significant improvement in adult ADHD symptoms.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top